What This Means for Patients and Providers
For oncologists and patients in India, the Enhertu approval provides an additional tool in the HER2-positive breast cancer treatment arsenal. Key practical considerations include:
- Treatment sequencing: Enhertu may be used in patients who have already received prior HER2-targeted therapies, offering a later-line option with a different mechanism of action.
- Access and availability: As an imported product distributed by AstraZeneca Pharma India, availability will depend on supply chain setup and distribution agreements. Patients should check with their oncologist or treating hospital for current availability.
- Cost considerations: Novel oncology therapies are typically priced at a premium. Patients should discuss insurance coverage, patient assistance programmes, and hospital pharmacy availability with their healthcare provider.
- Regulatory status monitoring: The CDSCO approval applies to the specific indication granted. Any off-label use should be discussed with a qualified oncologist and may not be covered by insurance.
Sources
This article is based on coverage from the following sources reporting on the CDSCO approval of AstraZeneca’s Enhertu for HER2-positive breast cancer:
- Medical Dialogues — “CDSCO Approves AstraZeneca’s Enhertu for Neoadjuvant HER2-Positive Breast Cancer” (July 28, 2026)
- Indian Pharma Post — “AstraZeneca gets CDSCO nod for expanded Enhertu indication in HER2-positive breast cancer” (July 28, 2026)
- CNBC TV18 — “AstraZeneca Pharma India gets CDSCO nod to import and distribute breast cancer treatment drug” (July 28, 2026)
- NDTV Profit — “AstraZeneca Pharma Gets CDSCO Nod To Sell Enhertu For Breast Cancer” (August 8, 2026)
- The Economic Times — “AstraZeneca’s Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer” (June 11, 2026) and “Intas gets CDSCO nod for breast cancer drug Trastuzumab Emtansine” (July 22, 2026)
- scanx.trade / ANI News — “AstraZeneca gets CDSCO nod for Enhertu for breast cancer” (September 13, 2026)
For more information, contact IMSDA at contact@indiamedicine.org.
India’s Broader Oncology Drug Landscape
The Enhertu approval comes amid a broader pattern of CDSCO activity on cancer drugs throughout 2026. In July 2026, the CDSCO also cleared expanded use of Intas Pharma’s Trastuzumab Emtansine (another HER2-targeted ADC) for breast cancer, as reported by The Economic Times (July 22, 2026). These approvals reflect the regulator’s increasing focus on expanding access to modern oncology therapies in the Indian market.
India’s pharmaceutical industry is the world’s largest provider of generic medicines by volume, but access to novel targeted therapies and antibody-drug conjugates has historically lagged behind regulated markets. Each new oncology drug approval by the CDSCO represents a stepwise expansion of treatment options available to Indian oncologists and patients.
What This Means for Patients and Providers
For oncologists and patients in India, the Enhertu approval provides an additional tool in the HER2-positive breast cancer treatment arsenal. Key practical considerations include:
- Treatment sequencing: Enhertu may be used in patients who have already received prior HER2-targeted therapies, offering a later-line option with a different mechanism of action.
- Access and availability: As an imported product distributed by AstraZeneca Pharma India, availability will depend on supply chain setup and distribution agreements. Patients should check with their oncologist or treating hospital for current availability.
- Cost considerations: Novel oncology therapies are typically priced at a premium. Patients should discuss insurance coverage, patient assistance programmes, and hospital pharmacy availability with their healthcare provider.
- Regulatory status monitoring: The CDSCO approval applies to the specific indication granted. Any off-label use should be discussed with a qualified oncologist and may not be covered by insurance.
Sources
This article is based on coverage from the following sources reporting on the CDSCO approval of AstraZeneca’s Enhertu for HER2-positive breast cancer:
- Medical Dialogues — “CDSCO Approves AstraZeneca’s Enhertu for Neoadjuvant HER2-Positive Breast Cancer” (July 28, 2026)
- Indian Pharma Post — “AstraZeneca gets CDSCO nod for expanded Enhertu indication in HER2-positive breast cancer” (July 28, 2026)
- CNBC TV18 — “AstraZeneca Pharma India gets CDSCO nod to import and distribute breast cancer treatment drug” (July 28, 2026)
- NDTV Profit — “AstraZeneca Pharma Gets CDSCO Nod To Sell Enhertu For Breast Cancer” (August 8, 2026)
- The Economic Times — “AstraZeneca’s Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer” (June 11, 2026) and “Intas gets CDSCO nod for breast cancer drug Trastuzumab Emtansine” (July 22, 2026)
- scanx.trade / ANI News — “AstraZeneca gets CDSCO nod for Enhertu for breast cancer” (September 13, 2026)
For more information, contact IMSDA at contact@indiamedicine.org.
HER2-Positive Breast Cancer in India
Breast cancer is the most common cancer among Indian women, accounting for a significant proportion of new cancer cases each year. HER2-positive breast cancer, while a subset of all breast cancers, is an aggressive form that requires targeted therapy for optimal outcomes.
Prior to this approval, Indian patients with HER2-positive breast cancer had access to trastuzumab (Herceptin) and pertuzumab-based regimens. Enhertu represents a newer generation of HER2-targeted therapy with demonstrated efficacy in patients who have progressed on earlier treatments, as shown in international clinical trials.
India’s Broader Oncology Drug Landscape
The Enhertu approval comes amid a broader pattern of CDSCO activity on cancer drugs throughout 2026. In July 2026, the CDSCO also cleared expanded use of Intas Pharma’s Trastuzumab Emtansine (another HER2-targeted ADC) for breast cancer, as reported by The Economic Times (July 22, 2026). These approvals reflect the regulator’s increasing focus on expanding access to modern oncology therapies in the Indian market.
India’s pharmaceutical industry is the world’s largest provider of generic medicines by volume, but access to novel targeted therapies and antibody-drug conjugates has historically lagged behind regulated markets. Each new oncology drug approval by the CDSCO represents a stepwise expansion of treatment options available to Indian oncologists and patients.
What This Means for Patients and Providers
For oncologists and patients in India, the Enhertu approval provides an additional tool in the HER2-positive breast cancer treatment arsenal. Key practical considerations include:
- Treatment sequencing: Enhertu may be used in patients who have already received prior HER2-targeted therapies, offering a later-line option with a different mechanism of action.
- Access and availability: As an imported product distributed by AstraZeneca Pharma India, availability will depend on supply chain setup and distribution agreements. Patients should check with their oncologist or treating hospital for current availability.
- Cost considerations: Novel oncology therapies are typically priced at a premium. Patients should discuss insurance coverage, patient assistance programmes, and hospital pharmacy availability with their healthcare provider.
- Regulatory status monitoring: The CDSCO approval applies to the specific indication granted. Any off-label use should be discussed with a qualified oncologist and may not be covered by insurance.
Sources
This article is based on coverage from the following sources reporting on the CDSCO approval of AstraZeneca’s Enhertu for HER2-positive breast cancer:
- Medical Dialogues — “CDSCO Approves AstraZeneca’s Enhertu for Neoadjuvant HER2-Positive Breast Cancer” (July 28, 2026)
- Indian Pharma Post — “AstraZeneca gets CDSCO nod for expanded Enhertu indication in HER2-positive breast cancer” (July 28, 2026)
- CNBC TV18 — “AstraZeneca Pharma India gets CDSCO nod to import and distribute breast cancer treatment drug” (July 28, 2026)
- NDTV Profit — “AstraZeneca Pharma Gets CDSCO Nod To Sell Enhertu For Breast Cancer” (August 8, 2026)
- The Economic Times — “AstraZeneca’s Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer” (June 11, 2026) and “Intas gets CDSCO nod for breast cancer drug Trastuzumab Emtansine” (July 22, 2026)
- scanx.trade / ANI News — “AstraZeneca gets CDSCO nod for Enhertu for breast cancer” (September 13, 2026)
For more information, contact IMSDA at contact@indiamedicine.org.
The CDSCO Approval: Scope and Significance
The CDSCO’s approval covers AstraZeneca Pharma India’s application to import and distribute Enhertu in India. According to reporting by Medical Dialogues (July 28, 2026) and NDTV Profit (August 8, 2026), the approval was specifically for the neoadjuvant treatment of HER2-positive breast cancer in the Stage II/III setting — meaning the drug can be used before surgery to shrink tumours and improve surgical outcomes.
The Economic Times (June 11, 2026) had earlier reported that Enhertu received regulatory approval in India for first-line HER2-positive breast cancer, indicating that the CDSCO approval process for this drug has been progressing through multiple indication stages throughout 2026.
HER2-Positive Breast Cancer in India
Breast cancer is the most common cancer among Indian women, accounting for a significant proportion of new cancer cases each year. HER2-positive breast cancer, while a subset of all breast cancers, is an aggressive form that requires targeted therapy for optimal outcomes.
Prior to this approval, Indian patients with HER2-positive breast cancer had access to trastuzumab (Herceptin) and pertuzumab-based regimens. Enhertu represents a newer generation of HER2-targeted therapy with demonstrated efficacy in patients who have progressed on earlier treatments, as shown in international clinical trials.
India’s Broader Oncology Drug Landscape
The Enhertu approval comes amid a broader pattern of CDSCO activity on cancer drugs throughout 2026. In July 2026, the CDSCO also cleared expanded use of Intas Pharma’s Trastuzumab Emtansine (another HER2-targeted ADC) for breast cancer, as reported by The Economic Times (July 22, 2026). These approvals reflect the regulator’s increasing focus on expanding access to modern oncology therapies in the Indian market.
India’s pharmaceutical industry is the world’s largest provider of generic medicines by volume, but access to novel targeted therapies and antibody-drug conjugates has historically lagged behind regulated markets. Each new oncology drug approval by the CDSCO represents a stepwise expansion of treatment options available to Indian oncologists and patients.
What This Means for Patients and Providers
For oncologists and patients in India, the Enhertu approval provides an additional tool in the HER2-positive breast cancer treatment arsenal. Key practical considerations include:
- Treatment sequencing: Enhertu may be used in patients who have already received prior HER2-targeted therapies, offering a later-line option with a different mechanism of action.
- Access and availability: As an imported product distributed by AstraZeneca Pharma India, availability will depend on supply chain setup and distribution agreements. Patients should check with their oncologist or treating hospital for current availability.
- Cost considerations: Novel oncology therapies are typically priced at a premium. Patients should discuss insurance coverage, patient assistance programmes, and hospital pharmacy availability with their healthcare provider.
- Regulatory status monitoring: The CDSCO approval applies to the specific indication granted. Any off-label use should be discussed with a qualified oncologist and may not be covered by insurance.
Sources
This article is based on coverage from the following sources reporting on the CDSCO approval of AstraZeneca’s Enhertu for HER2-positive breast cancer:
- Medical Dialogues — “CDSCO Approves AstraZeneca’s Enhertu for Neoadjuvant HER2-Positive Breast Cancer” (July 28, 2026)
- Indian Pharma Post — “AstraZeneca gets CDSCO nod for expanded Enhertu indication in HER2-positive breast cancer” (July 28, 2026)
- CNBC TV18 — “AstraZeneca Pharma India gets CDSCO nod to import and distribute breast cancer treatment drug” (July 28, 2026)
- NDTV Profit — “AstraZeneca Pharma Gets CDSCO Nod To Sell Enhertu For Breast Cancer” (August 8, 2026)
- The Economic Times — “AstraZeneca’s Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer” (June 11, 2026) and “Intas gets CDSCO nod for breast cancer drug Trastuzumab Emtansine” (July 22, 2026)
- scanx.trade / ANI News — “AstraZeneca gets CDSCO nod for Enhertu for breast cancer” (September 13, 2026)
For more information, contact IMSDA at contact@indiamedicine.org.
What Is Enhertu and How It Works
Enhertu is a targeted antibody-drug conjugate (ADC) that combines a monoclonal antibody (trastuzumab) with a cytotoxic chemotherapy agent (deruxtecan). It is designed to target the HER2 protein, which is overexpressed in approximately 15-20% of breast cancers, according to established oncology literature. The drug delivers chemotherapy directly into HER2-positive cancer cells while sparing healthy tissue, representing a precision-medicine approach to breast cancer treatment.
Enhertu has been approved in multiple countries including the United States (FDA, 2019) and the European Union (EMA) for various HER2-positive breast cancer indications. The CDSCO approval brings this treatment option to Indian patients who previously had limited access to this class of therapy.
The CDSCO Approval: Scope and Significance
The CDSCO’s approval covers AstraZeneca Pharma India’s application to import and distribute Enhertu in India. According to reporting by Medical Dialogues (July 28, 2026) and NDTV Profit (August 8, 2026), the approval was specifically for the neoadjuvant treatment of HER2-positive breast cancer in the Stage II/III setting — meaning the drug can be used before surgery to shrink tumours and improve surgical outcomes.
The Economic Times (June 11, 2026) had earlier reported that Enhertu received regulatory approval in India for first-line HER2-positive breast cancer, indicating that the CDSCO approval process for this drug has been progressing through multiple indication stages throughout 2026.
HER2-Positive Breast Cancer in India
Breast cancer is the most common cancer among Indian women, accounting for a significant proportion of new cancer cases each year. HER2-positive breast cancer, while a subset of all breast cancers, is an aggressive form that requires targeted therapy for optimal outcomes.
Prior to this approval, Indian patients with HER2-positive breast cancer had access to trastuzumab (Herceptin) and pertuzumab-based regimens. Enhertu represents a newer generation of HER2-targeted therapy with demonstrated efficacy in patients who have progressed on earlier treatments, as shown in international clinical trials.
India’s Broader Oncology Drug Landscape
The Enhertu approval comes amid a broader pattern of CDSCO activity on cancer drugs throughout 2026. In July 2026, the CDSCO also cleared expanded use of Intas Pharma’s Trastuzumab Emtansine (another HER2-targeted ADC) for breast cancer, as reported by The Economic Times (July 22, 2026). These approvals reflect the regulator’s increasing focus on expanding access to modern oncology therapies in the Indian market.
India’s pharmaceutical industry is the world’s largest provider of generic medicines by volume, but access to novel targeted therapies and antibody-drug conjugates has historically lagged behind regulated markets. Each new oncology drug approval by the CDSCO represents a stepwise expansion of treatment options available to Indian oncologists and patients.
What This Means for Patients and Providers
For oncologists and patients in India, the Enhertu approval provides an additional tool in the HER2-positive breast cancer treatment arsenal. Key practical considerations include:
- Treatment sequencing: Enhertu may be used in patients who have already received prior HER2-targeted therapies, offering a later-line option with a different mechanism of action.
- Access and availability: As an imported product distributed by AstraZeneca Pharma India, availability will depend on supply chain setup and distribution agreements. Patients should check with their oncologist or treating hospital for current availability.
- Cost considerations: Novel oncology therapies are typically priced at a premium. Patients should discuss insurance coverage, patient assistance programmes, and hospital pharmacy availability with their healthcare provider.
- Regulatory status monitoring: The CDSCO approval applies to the specific indication granted. Any off-label use should be discussed with a qualified oncologist and may not be covered by insurance.
Sources
This article is based on coverage from the following sources reporting on the CDSCO approval of AstraZeneca’s Enhertu for HER2-positive breast cancer:
- Medical Dialogues — “CDSCO Approves AstraZeneca’s Enhertu for Neoadjuvant HER2-Positive Breast Cancer” (July 28, 2026)
- Indian Pharma Post — “AstraZeneca gets CDSCO nod for expanded Enhertu indication in HER2-positive breast cancer” (July 28, 2026)
- CNBC TV18 — “AstraZeneca Pharma India gets CDSCO nod to import and distribute breast cancer treatment drug” (July 28, 2026)
- NDTV Profit — “AstraZeneca Pharma Gets CDSCO Nod To Sell Enhertu For Breast Cancer” (August 8, 2026)
- The Economic Times — “AstraZeneca’s Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer” (June 11, 2026) and “Intas gets CDSCO nod for breast cancer drug Trastuzumab Emtansine” (July 22, 2026)
- scanx.trade / ANI News — “AstraZeneca gets CDSCO nod for Enhertu for breast cancer” (September 13, 2026)
For more information, contact IMSDA at contact@indiamedicine.org.
The Central Drugs Standard Control Organisation (CDSCO) has approved AstraZeneca Pharma India’s application to import and distribute Enhertu (trastuzumab deruxtecan) for the treatment of HER2-positive breast cancer, marking a significant addition to India’s oncology drug portfolio. The approval was reported by multiple industry publications on September 13, 2026.
What Is Enhertu and How It Works
Enhertu is a targeted antibody-drug conjugate (ADC) that combines a monoclonal antibody (trastuzumab) with a cytotoxic chemotherapy agent (deruxtecan). It is designed to target the HER2 protein, which is overexpressed in approximately 15-20% of breast cancers, according to established oncology literature. The drug delivers chemotherapy directly into HER2-positive cancer cells while sparing healthy tissue, representing a precision-medicine approach to breast cancer treatment.
Enhertu has been approved in multiple countries including the United States (FDA, 2019) and the European Union (EMA) for various HER2-positive breast cancer indications. The CDSCO approval brings this treatment option to Indian patients who previously had limited access to this class of therapy.
The CDSCO Approval: Scope and Significance
The CDSCO’s approval covers AstraZeneca Pharma India’s application to import and distribute Enhertu in India. According to reporting by Medical Dialogues (July 28, 2026) and NDTV Profit (August 8, 2026), the approval was specifically for the neoadjuvant treatment of HER2-positive breast cancer in the Stage II/III setting — meaning the drug can be used before surgery to shrink tumours and improve surgical outcomes.
The Economic Times (June 11, 2026) had earlier reported that Enhertu received regulatory approval in India for first-line HER2-positive breast cancer, indicating that the CDSCO approval process for this drug has been progressing through multiple indication stages throughout 2026.
HER2-Positive Breast Cancer in India
Breast cancer is the most common cancer among Indian women, accounting for a significant proportion of new cancer cases each year. HER2-positive breast cancer, while a subset of all breast cancers, is an aggressive form that requires targeted therapy for optimal outcomes.
Prior to this approval, Indian patients with HER2-positive breast cancer had access to trastuzumab (Herceptin) and pertuzumab-based regimens. Enhertu represents a newer generation of HER2-targeted therapy with demonstrated efficacy in patients who have progressed on earlier treatments, as shown in international clinical trials.
India’s Broader Oncology Drug Landscape
The Enhertu approval comes amid a broader pattern of CDSCO activity on cancer drugs throughout 2026. In July 2026, the CDSCO also cleared expanded use of Intas Pharma’s Trastuzumab Emtansine (another HER2-targeted ADC) for breast cancer, as reported by The Economic Times (July 22, 2026). These approvals reflect the regulator’s increasing focus on expanding access to modern oncology therapies in the Indian market.
India’s pharmaceutical industry is the world’s largest provider of generic medicines by volume, but access to novel targeted therapies and antibody-drug conjugates has historically lagged behind regulated markets. Each new oncology drug approval by the CDSCO represents a stepwise expansion of treatment options available to Indian oncologists and patients.
What This Means for Patients and Providers
For oncologists and patients in India, the Enhertu approval provides an additional tool in the HER2-positive breast cancer treatment arsenal. Key practical considerations include:
- Treatment sequencing: Enhertu may be used in patients who have already received prior HER2-targeted therapies, offering a later-line option with a different mechanism of action.
- Access and availability: As an imported product distributed by AstraZeneca Pharma India, availability will depend on supply chain setup and distribution agreements. Patients should check with their oncologist or treating hospital for current availability.
- Cost considerations: Novel oncology therapies are typically priced at a premium. Patients should discuss insurance coverage, patient assistance programmes, and hospital pharmacy availability with their healthcare provider.
- Regulatory status monitoring: The CDSCO approval applies to the specific indication granted. Any off-label use should be discussed with a qualified oncologist and may not be covered by insurance.
Sources
This article is based on coverage from the following sources reporting on the CDSCO approval of AstraZeneca’s Enhertu for HER2-positive breast cancer:
- Medical Dialogues — “CDSCO Approves AstraZeneca’s Enhertu for Neoadjuvant HER2-Positive Breast Cancer” (July 28, 2026)
- Indian Pharma Post — “AstraZeneca gets CDSCO nod for expanded Enhertu indication in HER2-positive breast cancer” (July 28, 2026)
- CNBC TV18 — “AstraZeneca Pharma India gets CDSCO nod to import and distribute breast cancer treatment drug” (July 28, 2026)
- NDTV Profit — “AstraZeneca Pharma Gets CDSCO Nod To Sell Enhertu For Breast Cancer” (August 8, 2026)
- The Economic Times — “AstraZeneca’s Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer” (June 11, 2026) and “Intas gets CDSCO nod for breast cancer drug Trastuzumab Emtansine” (July 22, 2026)
- scanx.trade / ANI News — “AstraZeneca gets CDSCO nod for Enhertu for breast cancer” (September 13, 2026)
For more information, contact IMSDA at contact@indiamedicine.org.